Xlife Sciences AG · ISIN: CH0461929603 · EQS - adhoc news

Xlife Sciences AG enables international co-investors to enter the stock and is planning a dual listing on the London Stock Exchange Group (LSEG)

Zurich, 30th of September 2024: The management of Xlife Sciences AG (SIX:XLS) was commissioned on September 3, 2024, after an intensive review of all available options and offers from the Board of Directors, to implement a strategy to increase market capitalization and, consequently, the stock price, as well as the liquidity and tradability of the stock. In close coordination with new international co-investors, a dual listing on the London Stock Exchange Group (LSEG) is being developed as the f...

SIX:XLS Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Xlife Sciences AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
30 September 2024 08:00PM
Xlife Sciences AG enables international co-investors to enter the stock and is planning a dual listing on the London Stock Exchange Group (LSEG)
CH0461929603
Zurich, 30th of September 2024: The management of Xlife Sciences AG (SIX:XLS) was commissioned on September 3, 2024, after an intensive review of all available options and offers from the Board of Directors, to implement a strategy to increase market capitalization and, consequently, the stock price, as well as the liquidity and tradability of the ...
Xlife Sciences AG
About the publication
19 September 2024 07:00AM
Successful First Half of 2024 with Strategic Progress and Solid Financial Figures
CH0461929603
Zurich, 19th of September 2024: Xlife Sciences AG (SIX: XLS) today published its 2024 Half-Year Report and announced significant progress in its business development. Despite a challenging market environment, the company was able to further expand its innovative strength and advance new partnerships and developments within its diversified portfolio...
Xlife Sciences AG
About the publication
19 September 2024 07:00AM
Successful First Half of 2024 with Strategic Progress and Solid Financial Figures
CH0461929603
Zurich, 19th of September 2024: Xlife Sciences AG (SIX: XLS) today published its 2024 Half-Year Report and announced significant progress in its business development. Despite a challenging market environment, the company was able to further expand its innovative strength and advance new partnerships and developments within its diversified portfolio...
Xlife Sciences AG
About the publication
03 September 2024 07:00AM
Xlife Sciences AG Completes Strategic Review Process by Q3 2024
CH0461929603
Zurich, 3rd of September 2024: Xlife Sciences AG (SIX: XLS) today announced that the Board of Directors has completed the strategic review and, as of September 2, 2024, has tasked management with implementing the process. The shareholders will be informed of the next steps by September 30, 2024, at the latest. The size and diversity of the portfoli...
Xlife Sciences AG
About the publication
28 June 2024 06:00PM
Successful General Assembly and New Trading Hours on the Sparks Segment of SIX
CH0461929603
Xlife Sciences AG / Key word(s): AGMEGM Xlife Sciences AG: Successful General Assembly and New Trading Hours on the Sparks Segment of SIX 28.06.2024 / 18:00 CET/CEST Zurich, 28th of June 2024: Xlife Sciences AG (SIX: XLS), a leading company in the development and commercialization of technologies and therapies in the li...
Xlife Sciences AG
About the publication
28 June 2024 06:00PM
Successful General Assembly and New Trading Hours on the Sparks Segment of SIX
CH0461929603
Xlife Sciences AG / Key word(s): AGMEGM Xlife Sciences AG: Successful General Assembly and New Trading Hours on the Sparks Segment of SIX 28.06.2024 / 18:00 CET/CEST Zurich, 28th of June 2024: Xlife Sciences AG (SIX: XLS), a leading company in the development and commercialization of technologies and therapies in the li...
Xlife Sciences AG
About the publication
26 June 2024 07:00AM
Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness
CH0461929603
Xlife Sciences AG / Key word(s): Market launch/Product Launch Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness 26.06.2024 / 07:00 CET/CEST Zurich, 26th of June 2024: Xlife Sciences AG announces significant progress in the development and application of innovat...
Xlife Sciences AG
About the publication
26 June 2024 07:00AM
Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness
CH0461929603
Xlife Sciences AG / Key word(s): Market launch/Product Launch Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness 26.06.2024 / 07:00 CET/CEST Zurich, 26th of June 2024: Xlife Sciences AG announces significant progress in the development and application of innovat...
Xlife Sciences AG
About the publication
27 May 2024 07:00AM
Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH
CH0461929603
Xlife Sciences AG / Key word(s): Alliance/Merger Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH 27.05.2024 / 07:00 CET/CEST Zurich, 27th of May 2024: Xlife Sciences AG announces the merger of its portfolio company, palleos healthcare GmbH, with OCT Clinical GmbH. This ...
Xlife Sciences AG
About the publication
30 April 2024 07:00AM
Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report
CH0461929603
Zurich, 30st of April 2024: Xlife Sciences AG (SIX: XLS) released the 2023 Valuation Report today, which assesses the company's portfolio as of the end of 2023. The evaluation was conducted by the independent consulting firm CYLAD Experts and covers 18 of the total 25 project companies of Xlife Sciences1. The assessment is primarily based on the ri...
Xlife Sciences AG
About the publication
23 April 2024 07:00AM
Xlife Sciences AG Publishes 2023 Annual Report
CH0461929603
Zurich, 23rd of April 2024: Xlife Sciences AG (SIX: XLS) reports on the financial and operational results of 2023 and provides insights into plans for 2024. Despite global uncertainties, the company remains resilient thanks to innovative projects and strategic partnerships, managing to complete its first cash-effective exits. Operational Progress i...
Xlife Sciences AG
About the publication
03 April 2024 05:00PM
Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland
CH0461929603
Xlife Sciences AG / Key word(s): Alliance/Contract Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland 03.04.2024 / 17:00 CET/CEST Xlife Sciences is pleased to announce a collaboration between its portfolio company, FUSE-AI, and T-Systems Switzerland. ...
Xlife Sciences AG
About the publication
05 February 2024 07:00AM
Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City
CH0461929603
Xlife Sciences AG / Key word(s): Alliance/Letter of Intent Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City 05.02.2024 / 07:00 CET/CEST Xlife Sciences AG is excited to announce the expansion of its existing collaboration with the Departme...
Xlife Sciences AG
About the publication
29 December 2023 05:45PM
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline
CH0461929603
Zurich, 29th of December 2023: VERAXA Biotech AG, a pioneering company in the development of superior antibody-based cancer therapies and a portfolio company of Xlife Sciences AG (SIX: XLS), is proud to announce the acquisition of Synimmune GmbH and its innovative Phase I antibody (FLYSYN) for the treatment of Acute Myeloid Leukemia (AML). This mar...
Xlife Sciences AG
About the publication
22 December 2023 07:00AM
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases
CH0461929603
Xlife Sciences AG / Key word(s): Research Update/Study Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases 22.12.2023 / 07:00 CET/CEST Xlife Sciences AG is pleased to announce that its project company, x-nuclear diagnostics GmbH, has reached a decisive milestone in ...
Xlife Sciences AG
About the publication
20 December 2023 07:00AM
Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases
CH0461929603
Xlife Sciences AG / Key word(s): Letter of Intent/Partnership Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases 20.12.2023 / 07:00 CET/CEST Xlife Sciences AG (SIX: XLS) and Quant Biomarke...
Xlife Sciences AG
About the publication
18 December 2023 07:00AM
Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Registration
CH0461929603
Zurich, 18th of December 2023: Xlife Sciences AG (SIX: XLS) achieves EU MDR Class IIa registration with the portfolio company FUSE-AI GmbH and reaches a milestone for medical technology. The AI algorithm «Prostate.Carcinoma.ai» from FUSE-AI GmbH can analyze a multitude of radiological images in a very short time with a lower error rate than the hum...
Xlife Sciences AG
About the publication
18 October 2023 07:00AM
Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million
CH0461929603
Zurich, 18th of October 2023: Xlife Sciences AG (SIX: XLS) has secured a strategic collaboration with 4D Lifetec AG that marks a transformative phase in the healthcare sector, fusing financial capabilities with avant-garde technology, aimed at revolutionizing early cancer detection. The agreement involves a two-pronged approach: Firstly, 4D Lifete...
Xlife Sciences AG
About the publication
29 September 2023 07:00AM
ESG Report shows status quo and outlines path for future sustainability improvements Media Release Zurich, September 29, 2023
CH0461929603
Xlife Sciences AG / Key word(s): Sustainability/ESG ESG Report shows status quo and outlines path for future sustainability improvements Media Release Zurich, September 29, 2023 29.09.2023 / 07:00 CET/CEST Xlife Sciences (SIX: XLS) today published its inaugural report on Environmental, Social and Governance (...
Xlife Sciences AG
About the publication
21 September 2023 07:00AM
Xlife Sciences with significant progress in H1 2023
CH0461929603
Xlife Sciences (SIX: XLS) today reported on its operational progress in H1 2023 and published its key financial figures for the reporting period. Xlife Sciences’ full half-year report 2023 is available for download as a PDF document at https://www.xlifesciences.ch/en/news-and-key-figures in the “Financial Reports” section.  Operational Highlights ...
Xlife Sciences AG
About the publication
17 August 2023 09:45AM
Collaboration of Xlife Sciences and the Department of Health – Abu Dhabi to drive global innovations in the life sciences sector
CH0461929603
Abu Dhabi, United Arab Emirates, 16th of August 2023: Xlife Sciences AG (SIX: XLS) signed a Memorandum of Understanding (MoU) with the regulator of the healthcare sector in the Emirate Abu Dhabi, the Department of Health – Abu Dhabi (DoH). This signed agreement, formalized at the Department's central headquarters, aims to directly enhance patient e...
Xlife Sciences AG
About the publication
20 June 2023 05:00PM
shareholders approved all motions at today’s AGM 2023
CH0461929603
Xlife Sciences AG / Key word(s): AGMEGM Media Release Zurich, June 20, 2023   Xlife Sciences: shareholders approved all motions at today’s AGM 2023 20.06.2023 / 17:00 CET/CEST Xlife Sciences AG (SIX: XLS) announces that its shareholders approved all motions on the agenda of the Ordinary Annual General Meeting (AGM) 2023 that ...
Xlife Sciences AG
About the publication
20 June 2023 05:00PM
shareholders approved all motions at today’s AGM 2023
CH0461929603
Xlife Sciences AG / Key word(s): AGMEGM Media Release Zurich, June 20, 2023   Xlife Sciences: shareholders approved all motions at today’s AGM 2023 20.06.2023 / 17:00 CET/CEST Xlife Sciences AG (SIX: XLS) announces that its shareholders approved all motions on the agenda of the Ordinary Annual General Meeting (AGM) 2023 that ...
Xlife Sciences AG
About the publication
26 May 2023 07:00AM
Xlife Sciences publishes agenda for Annual General Meeting 2023
CH0461929603
Xlife Sciences AG (SIX: XLS) today published the agenda of its upcoming Ordinary Annual General Meeting 2023 that will take place on Tuesday, June 20, as of 10 am CET at Hotel “Schweizerhof” in Zurich, Switzerland: The voting items for the Annual General Meeting 2023 include, among others, the approval of the annual financial statements and the co...
Xlife Sciences AG
About the publication
26 May 2023 07:00AM
Xlife Sciences publishes agenda for Annual General Meeting 2023
CH0461929603
Xlife Sciences AG (SIX: XLS) today published the agenda of its upcoming Ordinary Annual General Meeting 2023 that will take place on Tuesday, June 20, as of 10 am CET at Hotel “Schweizerhof” in Zurich, Switzerland: The voting items for the Annual General Meeting 2023 include, among others, the approval of the annual financial statements and the co...
Xlife Sciences AG
About the publication
27 April 2023 07:00AM
Valuation Report 2022 confirms and emphasizes long-term portfolio potential
CH0461929603
Xlife Sciences AG (SIX: XLS) today published the full Valuation Report 2022, which values the company's portfolio as of the end of 2022. The valuation was carried out by the independent consultancy Cylad Experts and covers 20 of Xlife Sciences’ 26 project companies.[1] The valuation is primarily based on the risk-adjusted net present value (NPV), t...
Xlife Sciences AG
About the publication
27 April 2023 07:00AM
Valuation Report 2022 confirms and emphasizes long-term portfolio potential
CH0461929603
Xlife Sciences AG (SIX: XLS) today published the full Valuation Report 2022, which values the company's portfolio as of the end of 2022. The valuation was carried out by the independent consultancy Cylad Experts and covers 20 of Xlife Sciences’ 26 project companies.[1] The valuation is primarily based on the risk-adjusted net present value (NPV), t...
Xlife Sciences AG
About the publication
20 April 2023 07:00AM
Xlife Sciences publishes 2022 results and 2023 outlook
CH0461929603
Xlife Sciences AG (SIX: XLS) today reported its 2022 results and 2023 outlook. The company also published the independent valuation report covering its project portfolio as of December 31, 2022. Operational progress in 2022 As at December 31, 2022, Xlife Sciences had 26 project companies. Among other things, they made the following pleasing progre...
Xlife Sciences AG
About the publication
20 April 2023 07:00AM
Xlife Sciences publishes 2022 results and 2023 outlook
CH0461929603
Xlife Sciences AG (SIX: XLS) today reported its 2022 results and 2023 outlook. The company also published the independent valuation report covering its project portfolio as of December 31, 2022. Operational progress in 2022 As at December 31, 2022, Xlife Sciences had 26 project companies. Among other things, they made the following pleasing progre...
Xlife Sciences AG
About the publication
16 February 2023 07:00AM
saniva diagnostics receives approval from the US FDA for its medical product NeuroMex
CH0461929603
Medical Screening Device Set to Measure Complex Neurocognitive Performance for Early Detection of Severe Neurodegenerative Diseases Such as Parkinson's or Alzheimer's saniva diagnostics, a portfolio company of Xlife Sciences (SIX: XLS), has received the 513(g) approval from the US Food and Drug Administration (FDA) to market and sell its proprietar...
Xlife Sciences AG
About the publication
16 February 2023 07:00AM
saniva diagnostics receives approval from the US FDA for its medical product NeuroMex
CH0461929603
Medical Screening Device Set to Measure Complex Neurocognitive Performance for Early Detection of Severe Neurodegenerative Diseases Such as Parkinson's or Alzheimer's saniva diagnostics, a portfolio company of Xlife Sciences (SIX: XLS), has received the 513(g) approval from the US Food and Drug Administration (FDA) to market and sell its proprietar...
Xlife Sciences AG
About the publication
23 January 2023 07:00AM
Stifel initiates research coverage of Xlife Sciences
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous Stifel initiates research coverage of Xlife Sciences 23.01.2023 / 07:00 CET/CEST   The renowned investment bank Stifel commenced its research coverage of Xife Sciences (SIX: XLS). The corresponding initial analyst report rates Xlife Sciences' stock with a “Buy” rating and calls for ...
Xlife Sciences AG
About the publication
20 January 2023 07:00AM
Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle
CH0461929603
Xlife Sciences AG / Key word(s): Patent Xlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle 20.01.2023 / 07:00 CET/CEST Xlife Sciences AG (SIX: XLS) announced today that its Swiss portfolio company Axenoll Life Sciences AG has been granted a strategically si...
Xlife Sciences AG
About the publication
16 January 2023 07:00AM
Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS)
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS) 16.01.2023 / 07:00 CET/CEST Xlife Sciences' (SIX: XLS) portfolio company inflamed pharma has launched a research project to develop a potential therapy for amyotr...
Xlife Sciences AG
About the publication
01 December 2022 07:01AM
Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CEST Lysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Sciences and curasan (a l...
Xlife Sciences AG
About the publication
01 December 2022 07:01AM
Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CEST Lysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Sciences and curasan (a l...
Xlife Sciences AG
About the publication
28 November 2022 07:00AM
alytas therapeutics collaborates with spin-off from the German Diabetes Center
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous alytas therapeutics collaborates with spin-off from the German Diabetes Center 28.11.2022 / 07:00 CET/CEST Xlife Sciences’ (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of morbid obes...
Xlife Sciences AG
About the publication
28 November 2022 07:00AM
alytas therapeutics collaborates with spin-off from the German Diabetes Center
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous alytas therapeutics collaborates with spin-off from the German Diabetes Center 28.11.2022 / 07:00 CET/CEST Xlife Sciences’ (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of morbid obes...
Xlife Sciences AG
About the publication
21 November 2022 07:01AM
Xlife Sciences initiates a review of strategic options
CH0461929603
The Board of Directors of Xlife Sciences AG (SIX: XLS), a leading European life sciences incubator and accelerator based in Switzerland, has initiated a process to review strategic options, aimed at accelerating the company's business development, and increasing value for its stakeholders. This review will consider all options available to the comp...
Xlife Sciences AG
About the publication
21 November 2022 07:01AM
Xlife Sciences initiates a review of strategic options
CH0461929603
The Board of Directors of Xlife Sciences AG (SIX: XLS), a leading European life sciences incubator and accelerator based in Switzerland, has initiated a process to review strategic options, aimed at accelerating the company's business development, and increasing value for its stakeholders. This review will consider all options available to the comp...
Xlife Sciences AG
About the publication
01 November 2022 07:00AM
ProcCluster® from portfolio company inflamed pharma granted US patent
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous ProcCluster® from portfolio company inflamed pharma granted US patent 01.11.2022 / 07:00 CET/CEST   Xlife Sciences AG (SIX: XLS) announced today that its portfolio company inflamed pharma has been granted a patent by the United States Patent and Trademark Office (USPTO) for the manu...
Xlife Sciences AG
About the publication
01 November 2022 07:00AM
ProcCluster® from portfolio company inflamed pharma granted US patent
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous ProcCluster® from portfolio company inflamed pharma granted US patent 01.11.2022 / 07:00 CET/CEST   Xlife Sciences AG (SIX: XLS) announced today that its portfolio company inflamed pharma has been granted a patent by the United States Patent and Trademark Office (USPTO) for the manu...
Xlife Sciences AG
About the publication
28 September 2022 07:01AM
Xlife Sciences with pleasing progress in the first half of 2022
CH0461929603
Xlife Sciences (SIX: XLS) today published its results for the first half of 2022 ending 30 June 2022. Oliver R. Baumann, CEO Xlife Sciences, comments: “In implementing our strategy of bridging preclinical research & development to healthcare markets, we have achieved relevant steps despite a challenging market environment and can look back on s...
Xlife Sciences AG
About the publication
28 September 2022 07:01AM
Xlife Sciences with pleasing progress in the first half of 2022
CH0461929603
Xlife Sciences (SIX: XLS) today published its results for the first half of 2022 ending 30 June 2022. Oliver R. Baumann, CEO Xlife Sciences, comments: “In implementing our strategy of bridging preclinical research & development to healthcare markets, we have achieved relevant steps despite a challenging market environment and can look back on s...
Xlife Sciences AG
About the publication
26 September 2022 07:00AM
Project company Laxxon Medical achieves major milestone
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous Project company Laxxon Medical achieves major milestone 26.09.2022 / 07:00 CET/CEST   Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms Strengthening the Position of Laxxon Medical’s Intellectual Property in the Pharmaceutical Marke...
Xlife Sciences AG
About the publication
26 September 2022 07:00AM
Project company Laxxon Medical achieves major milestone
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous Project company Laxxon Medical achieves major milestone 26.09.2022 / 07:00 CET/CEST   Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms Strengthening the Position of Laxxon Medical’s Intellectual Property in the Pharmaceutical Marke...
Xlife Sciences AG
About the publication
21 September 2022 07:00AM
Xlife Sciences strengthens sustainability activities with ESG strategy
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous Xlife Sciences strengthens sustainability activities with ESG strategy 21.09.2022 / 07:00 CET/CEST One of the objectives of Xlife Sciences (SIX: XLS) is to significantly strengthen and further develop its existing sustainability activities on a strategic and operational level. For th...
Xlife Sciences AG
About the publication
21 September 2022 07:00AM
Xlife Sciences strengthens sustainability activities with ESG strategy
CH0461929603
Xlife Sciences AG / Key word(s): Miscellaneous Xlife Sciences strengthens sustainability activities with ESG strategy 21.09.2022 / 07:00 CET/CEST One of the objectives of Xlife Sciences (SIX: XLS) is to significantly strengthen and further develop its existing sustainability activities on a strategic and operational level. For th...
Xlife Sciences AG
About the publication
More Xlife Sciences AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN